The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is above average at 39.08x, Company’s 36-month beta value is 0.47.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B, and currently, short sellers hold a 0.21% ratio of that floaft. The average trading volume of AZN on July 22, 2024 was 4.30M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AZN) stock’s latest price update
Astrazeneca plc ADR (NASDAQ: AZN) has seen a rise in its stock price by 0.74 in relation to its previous close of 78.71. However, the company has experienced a 1.50% gain in its stock price over the last five trading sessions. proactiveinvestors.co.uk reported 2024-07-19 that AstraZeneca PLC (LSE:AZN) releases its quarterly results next Thursday in the wake of an Investor Day at which outlined its bold plan to almost double its turnover to $80 billion by the end of the decade bolstered by a strong pipeline of new drugs, particularly in oncology. Against this backdrop, and a strong financial performance in the first quarter, analysts are now asking whether the Anglo-Swedish drugs giant will upgrade its already bullish financial forecasts for 2024.
AZN’s Market Performance
AZN’s stock has risen by 1.50% in the past week, with a monthly rise of 0.93% and a quarterly rise of 15.67%. The volatility ratio for the week is 1.49% while the volatility levels for the last 30 days are 1.09% for Astrazeneca plc ADR The simple moving average for the last 20 days is 1.38% for AZN stock, with a simple moving average of 14.10% for the last 200 days.
Analysts’ Opinion of AZN
Many brokerage firms have already submitted their reports for AZN stocks, with Goldman repeating the rating for AZN by listing it as a “Buy.” The predicted price for AZN in the upcoming period, according to Goldman is $97 based on the research report published on May 30, 2024 of the current year 2024.
AZN Trading at 1.24% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.94% of loss for the given period.
Volatility was left at 1.09%, however, over the last 30 days, the volatility rate increased by 1.49%, as shares surge +0.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.85% upper at present.
During the last 5 trading sessions, AZN rose by +1.34%, which changed the moving average for the period of 200-days by +19.48% in comparison to the 20-day moving average, which settled at $78.23. In addition, Astrazeneca plc ADR saw 17.73% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.8 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 17.29, with 6.36 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 0.9. The interest coverage ratio of the stock is 5.41.
Currently, EBITDA for the company is 13.91 billion with net debt to EBITDA at 2.02. When we switch over and look at the enterprise to sales, we see a ratio of 5.72. The receivables turnover for the company is 3.89for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In a nutshell, Astrazeneca plc ADR (AZN) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
